Unexpected improvement of sexual dysfunction during atazanavir therapy [4]

AIDS

Volumn 20, Issue 8, 2006, Pages 1209-1210

  Colebunders, R ^a,b   Moerman, F ^a   Noestlinger C ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; NEVIRAPINE; PROTEINASE INHIBITOR;

CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SUBSTITUTION; EXPECTATION; GENERAL CONDITION IMPROVEMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LETTER; PRIORITY JOURNAL; SEXUAL DYSFUNCTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV PROTEASE INHIBITORS; HUMANS; MALE; OLIGOPEPTIDES; PYRIDINES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 33646885504     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000226968.96880.75     Document Type: Letter

References (2)

1. Bernai E, Masia M, Padilla S, Gutierrez F. Unexpected improvement of sexual dysfunction during atazanavir therapy. AIDS 2005; 19:1440-1441.
2. Colebunders R, Schrooten W, Desmet P, De Roo A, Dreezen C. Prevention of nevirapine-associated rash. Lancet 2001; 357:392-393.